Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1750149 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $2.21Day −4.33%Mkt cap $292M1Y +30.0%Off 52W high −12.6%Vol (1Y) 70.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest13.8% of sh out |
| Days to cover16.9d |
| 13F net flow (QoQ)+5.93% |
| Top-10 13F concentration65.5% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$51.0M |
| ROE−36.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+7.8% |
| 1Y+30.0% |
| 3Y−12.3% |
| 5Y−84.4% |
| Since incept. (ann.)−42.7% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)70.0% |
| Ann. volatility (3Y)99.3% |
| Sharpe (1Y)0.67 |
| Sharpe (3Y)0.46 |
| Max drawdown (1Y)−26.8% |
| Max drawdown (3Y)−68.0% |
| Beta (3Y vs SPY)0.61 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Sands Capital Alternatives, LLC | 13.0M | $22M | 9.86% | +0.0% |
| Soleus Capital Management, L.P. | 10.9M | $18M | 8.24% | +0.0% |
| Fairmount Funds Management LLC | 8.6M | $14M | 6.53% | +0.0% |
| Trails Edge Capital Partners, LP | 8.1M | $14M | 6.10% | +30.4% |
| ADAR1 Capital Management, LLC | 6.6M | $11M | 5.00% | −18.1% |
| Kalehua Capital Management LLC | 6.5M | $11M | 4.92% | +271.1% |
| BlackRock, Inc. | 6.3M | $11M | 4.77% | +90.7% |
| Blackstone Inc. | 5.9M | $10M | 4.50% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | −$0.10 | — | $0 | — |
| 2025-09-30 | 2025-11-14 | −$0.13 | — | $0 | — |
| 2025-06-30 | 2025-08-14 | −$0.11 | — | $0 | — |
| 2025-03-31 | 2025-05-14 | −$0.15 | — | $0 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
